View Financial HealthMabion 배당 및 자사주 매입배당 기준 점검 0/6Mabion 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • May 24First quarter 2026 earnings released: zł0.60 loss per share (vs zł0.94 loss in 1Q 2025)First quarter 2026 results: zł0.60 loss per share (improved from zł0.94 loss in 1Q 2025). Revenue: zł4.57m (up 68% from 1Q 2025). Net loss: zł9.74m (loss narrowed 36% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.공시 • Aug 25Mabion S.A. to Report First Half, 2025 Results on Sep 30, 2025Mabion S.A. announced that they will report first half, 2025 results on Sep 30, 2025공시 • Apr 25Mabion S.A., Annual General Meeting, May 26, 2025Mabion S.A., Annual General Meeting, May 26, 2025.Valuation Update With 7 Day Price Move • Nov 05Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to €2.55, the stock trades at a trailing P/E ratio of 18.9x. Average trailing P/E is 24x in the Biotechs industry in Europe. Total loss to shareholders of 84% over the past three years.Reported Earnings • Oct 29Third quarter 2024 earnings released: zł1.01 loss per share (vs zł0.67 profit in 3Q 2023)Third quarter 2024 results: zł1.01 loss per share (down from zł0.67 profit in 3Q 2023). Revenue: zł516.0k (down 98% from 3Q 2023). Net loss: zł16.3m (down 250% from profit in 3Q 2023). Revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 11Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł29.8m (down 17% from 2Q 2023). Net income: zł10.3m (down 33% from 2Q 2023). Profit margin: 35% (down from 42% in 2Q 2023). Revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.New Risk • Sep 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 100% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 100% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (€71.8m market cap, or US$79.2m).New Risk • Jul 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 112% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 112% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (€66.5m market cap, or US$72.4m).공시 • May 25Mabion S.A., Annual General Meeting, Jun 17, 2024Mabion S.A., Annual General Meeting, Jun 17, 2024.Reported Earnings • May 19First quarter 2024 earnings released: EPS: zł1.06 (vs zł1.02 in 1Q 2023)First quarter 2024 results: EPS: zł1.06 (up from zł1.02 in 1Q 2023). Revenue: zł34.0m (down 14% from 1Q 2023). Net income: zł17.5m (up 6.5% from 1Q 2023). Profit margin: 52% (up from 42% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €4.28, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 31x in the Biotechs industry in Europe. Total loss to shareholders of 57% over the past three years.Reported Earnings • Apr 18Full year 2023 earnings released: EPS: zł2.55 (vs zł1.44 in FY 2022)Full year 2023 results: EPS: zł2.55 (up from zł1.44 in FY 2022). Revenue: zł151.7m (down 7.5% from FY 2022). Net income: zł41.3m (up 78% from FY 2022). Profit margin: 27% (up from 14% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.공시 • Jan 12+ 3 more updatesMabion S.A. to Report Q3, 2024 Results on Nov 25, 2024Mabion S.A. announced that they will report Q3, 2024 results on Nov 25, 2024New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 28% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (€84.4m market cap, or US$91.3m).Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €4.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 25x in the Biotechs industry in Europe. Total returns to shareholders of 7.0% over the past year.New Risk • Nov 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 34% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risk Market cap is less than US$100m (€65.7m market cap, or US$71.2m).Reported Earnings • Sep 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł36.0m (down 18% from 2Q 2022). Net income: zł15.2m (up 198% from 2Q 2022). Profit margin: 42% (up from 12% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.공시 • Jun 13Mabion S.A., Annual General Meeting, Jun 13, 2023Mabion S.A., Annual General Meeting, Jun 13, 2023, at 14:00 Central European Standard Time.공시 • Jan 26+ 3 more updatesMabion S.A. to Report Fiscal Year 2022 Results on Apr 25, 2023Mabion S.A. announced that they will report fiscal year 2022 results at 5:30 PM, Central European Standard Time on Apr 25, 2023Valuation Update With 7 Day Price Move • Aug 11Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to €5.64, the stock trades at a trailing P/E ratio of 16.1x. Average forward P/E is 25x in the Biotechs industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.51 per share.Valuation Update With 7 Day Price Move • Jul 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €6.22, the stock trades at a trailing P/E ratio of 18.2x. Average forward P/E is 30x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past year.Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to €5.28, the stock trades at a trailing P/E ratio of 15x. Average forward P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 64% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.41 per share.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 27% share price decline to €4.51, the stock trades at a trailing P/E ratio of 12.7x. Average forward P/E is 31x in the Biotechs industry in Europe. Total loss to shareholders of 74% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.47 per share.공시 • May 27Mabion S.A., Annual General Meeting, Jun 21, 2022Mabion S.A., Annual General Meeting, Jun 21, 2022, at 11:00 Central European Standard Time.Breakeven Date Change • Apr 27Forecast breakeven date moved forward to 2022The analyst covering Mabion previously expected the company to break even in 2023. New forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Breakeven Date Change • Jul 27Forecast breakeven moved forward to 2022The 2 analysts covering Mabion previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 63% is required to achieve expected profit on schedule.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 272 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 272 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Mabion 배당 수익률 vs 시장272의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (272)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.7%업계 평균 (Biotechs)2.4%분석가 예측 (272) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 272 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 272 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 272 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 272 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 03:42종가2026/06/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Mabion S.A.는 7명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Beata Szparaga-WasniewskaBiuro maklerskie mBankuKamil KliszczBiuro maklerskie mBankuPawel PuchalskiErste Bank Polska S.A.4명의 분석가 더 보기
Reported Earnings • May 24First quarter 2026 earnings released: zł0.60 loss per share (vs zł0.94 loss in 1Q 2025)First quarter 2026 results: zł0.60 loss per share (improved from zł0.94 loss in 1Q 2025). Revenue: zł4.57m (up 68% from 1Q 2025). Net loss: zł9.74m (loss narrowed 36% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
공시 • Aug 25Mabion S.A. to Report First Half, 2025 Results on Sep 30, 2025Mabion S.A. announced that they will report first half, 2025 results on Sep 30, 2025
공시 • Apr 25Mabion S.A., Annual General Meeting, May 26, 2025Mabion S.A., Annual General Meeting, May 26, 2025.
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to €2.55, the stock trades at a trailing P/E ratio of 18.9x. Average trailing P/E is 24x in the Biotechs industry in Europe. Total loss to shareholders of 84% over the past three years.
Reported Earnings • Oct 29Third quarter 2024 earnings released: zł1.01 loss per share (vs zł0.67 profit in 3Q 2023)Third quarter 2024 results: zł1.01 loss per share (down from zł0.67 profit in 3Q 2023). Revenue: zł516.0k (down 98% from 3Q 2023). Net loss: zł16.3m (down 250% from profit in 3Q 2023). Revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 11Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł29.8m (down 17% from 2Q 2023). Net income: zł10.3m (down 33% from 2Q 2023). Profit margin: 35% (down from 42% in 2Q 2023). Revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
New Risk • Sep 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 100% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 100% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (€71.8m market cap, or US$79.2m).
New Risk • Jul 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 112% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 112% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (€66.5m market cap, or US$72.4m).
공시 • May 25Mabion S.A., Annual General Meeting, Jun 17, 2024Mabion S.A., Annual General Meeting, Jun 17, 2024.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: zł1.06 (vs zł1.02 in 1Q 2023)First quarter 2024 results: EPS: zł1.06 (up from zł1.02 in 1Q 2023). Revenue: zł34.0m (down 14% from 1Q 2023). Net income: zł17.5m (up 6.5% from 1Q 2023). Profit margin: 52% (up from 42% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €4.28, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 31x in the Biotechs industry in Europe. Total loss to shareholders of 57% over the past three years.
Reported Earnings • Apr 18Full year 2023 earnings released: EPS: zł2.55 (vs zł1.44 in FY 2022)Full year 2023 results: EPS: zł2.55 (up from zł1.44 in FY 2022). Revenue: zł151.7m (down 7.5% from FY 2022). Net income: zł41.3m (up 78% from FY 2022). Profit margin: 27% (up from 14% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
공시 • Jan 12+ 3 more updatesMabion S.A. to Report Q3, 2024 Results on Nov 25, 2024Mabion S.A. announced that they will report Q3, 2024 results on Nov 25, 2024
New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 28% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (€84.4m market cap, or US$91.3m).
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €4.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 25x in the Biotechs industry in Europe. Total returns to shareholders of 7.0% over the past year.
New Risk • Nov 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 34% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risk Market cap is less than US$100m (€65.7m market cap, or US$71.2m).
Reported Earnings • Sep 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł36.0m (down 18% from 2Q 2022). Net income: zł15.2m (up 198% from 2Q 2022). Profit margin: 42% (up from 12% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
공시 • Jun 13Mabion S.A., Annual General Meeting, Jun 13, 2023Mabion S.A., Annual General Meeting, Jun 13, 2023, at 14:00 Central European Standard Time.
공시 • Jan 26+ 3 more updatesMabion S.A. to Report Fiscal Year 2022 Results on Apr 25, 2023Mabion S.A. announced that they will report fiscal year 2022 results at 5:30 PM, Central European Standard Time on Apr 25, 2023
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to €5.64, the stock trades at a trailing P/E ratio of 16.1x. Average forward P/E is 25x in the Biotechs industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.51 per share.
Valuation Update With 7 Day Price Move • Jul 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €6.22, the stock trades at a trailing P/E ratio of 18.2x. Average forward P/E is 30x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past year.
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to €5.28, the stock trades at a trailing P/E ratio of 15x. Average forward P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 64% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.41 per share.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 27% share price decline to €4.51, the stock trades at a trailing P/E ratio of 12.7x. Average forward P/E is 31x in the Biotechs industry in Europe. Total loss to shareholders of 74% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.47 per share.
공시 • May 27Mabion S.A., Annual General Meeting, Jun 21, 2022Mabion S.A., Annual General Meeting, Jun 21, 2022, at 11:00 Central European Standard Time.
Breakeven Date Change • Apr 27Forecast breakeven date moved forward to 2022The analyst covering Mabion previously expected the company to break even in 2023. New forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Breakeven Date Change • Jul 27Forecast breakeven moved forward to 2022The 2 analysts covering Mabion previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 63% is required to achieve expected profit on schedule.